We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bim3.9
Bimagrumab Research
Mostly mechanism / observational
23 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Bimagrumab studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2014–2026 with a typical study size of 507 participants.
Based on 23 studies · 2 meta-analyses · 14 RCTs · 507 total participants
Confidence
High confidence
By outcome
Muscle & lean massPilot sIBM trial: a single dose raised thigh-muscle volume ~6.5% and lean mass ~5.7% vs placebo (Class I evidence ActRII blockade builds muscle in humans) · Within 8-16 weeks
Mostly mechanism / observational9 studies
Fat loss & metabolic
Mostly mechanism / observational7 studies
Safety profile
Mostly mechanism / observational3 studies
Active research area
14 studies in the last 5 years · Latest meta-analysis: 2025
201420202026
1Meta-Analysis2021
Spitz RW, Dankel SJ, Bell ZW, Wong V, Abe T, Kang M · Geriatr Gerontol Int (2021)
Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators. · Nature medicine (2026)
The least squares mean absolute changes in body weight at week 48 were -9.3 kg (bimagrumab 30 mg kg -1 ), -14.2 kg (semaglutide 2.4 mg) and -17.8 kg (bimagrumab 30 mg kg -1 plus semaglutide 2.4 mg-that is, high-dose combination) versus -3.3 kg (placebo) (all P < 0.001 versus placebo).
Continued improvements were observed through week 72.
Common adverse events for bimagrumab included muscle spasms, diarrhea and acne, and semaglutide was associated with nausea, diarrhea, constipation and fatigue.
In plain English: This narrative review discusses the justification for focus on lean mass preservation and reviews the status of relevant drugs in development.
Ryan DH. · Reviews in endocrine & metabolic disorders (2025)
The development of drugs targeting Nutrient Stimulated Hormone receptors has ushered in a dramatic change in our approach to weight management because of their ability to achieve weight losses of 10%, 20%, even 30% in significant numbers of patients.
Of weight lost with semaglutide, approximately 45% is from lean mass, while with tirzepatide, it is 25%.
Another approach under study is the use of MAPi - myostatin-activin pathway inhibitors.
In plain English: Preliminary findings are promising, but larger, controlled trials are necessary to confirm efficacy and safety before clinical implementation can be considered.
In plain English: For the time being, considerations like advanced age and prefrailty may affect the choice of suitable candidates in clinical practice for current and emerging anti-obesity medications due to the associated risk of sarcopenia.
Stefanakis K, Kokkorakis M, Mantzoros CS. · Metabolism: clinical and experimental (2024)
Similar to bariatric surgery, incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15-25 % weight loss in many patients, i.e., at a rate approaching that achieved with bariatric surgery.
However, over 25 % of total weight lost from both surgery and pharmacotherapy typically comes from fat-free mass, including skeletal muscle mass, which is often overlooked and can impair metabolic health and increase the risk of subsequent sarcopenic obesity.
Novel compounds in the pipeline, such as Bimagrumab, Trevogrumab, and Garetosmab-which inhibit activin and myostatin signaling-have demonstrated promise in preventing muscle loss while promoting fat loss.
In plain English: Future research should prioritize multimodal therapies, validated biomarkers, and AI-driven algorithms to individualize sarcopenia management in aging populations.
Liu X, Chen X, Cui J. · Clinical nutrition (Edinburgh, Scotland) (2025)
Sarcopenia, a progressive decline in skeletal muscle mass and function, has emerged as a critical geriatric syndrome affecting 10-40% of older adults, contributing to increased disability and mortality.
Pharmacological trials highlight selective androgen receptor modulators (SARMs) and myostatin inhibitors (e.g., bimagrumab) increasing lean mass by 3-5% in phase II studies, with GDF-15-neutralizing antibodies emerging as promising anti-catabolic agents.
However, clinical translation requires validation through large-scale trials.